Workflow
Globenewswire
icon
Search documents
First Advantage Releases Fourth Annual Sustainability Impact Report
Globenewswire· 2025-08-18 20:00
Core Insights - First Advantage Corporation released its 2024 Sustainability Impact Report, highlighting its commitment to responsible business practices and progress in environmental, community, and governance priorities [1][2] Group 1: Company Growth and Acquisitions - The 2024 report marks a milestone year for First Advantage, highlighted by the acquisition of Sterling Check Corp., which closed on October 31, 2024 [2] - The CEO emphasized that the combination with Sterling provides an opportunity for growth while maintaining a focus on purpose, responsibility, and impact [3] Group 2: Sustainability Efforts - The report outlines sustainability focus areas including people and community, environment and climate, governance and accountability, and policy and process [2] - The company conducted third-party assessments of Scope 1, 2, and 3 greenhouse gas emissions to align with the Task Force on Climate-related Financial Disclosures (TCFD) [5] Group 3: Employee Development and Inclusion - Following the acquisition, First Advantage updated its Culture & Inclusion priorities, expanding Employee Resource Groups into Employee Impact Groups [5] - Employees across 19 countries completed 131,740 training hours, leading to a 74% increase in the speed at which new hires became ready to work on live cases [5] Group 4: Data Privacy and Compliance - First Advantage maintained its ISO 27001 and ISO 27701 certifications, with Australian operations newly certified in 2024 [5] - The company earned Data Privacy Framework certifications across its EU, UK, and Swiss locations, reflecting its commitment to data protection [5] Group 5: Governance and Corporate Oversight - The company demonstrated strong governance through a well-qualified board of directors overseeing various committees [5]
MYR Group Inc. to Participate in KeyBanc Taking Charge: Energy Transition Symposium in September
Globenewswire· 2025-08-18 20:00
Company Overview - MYR Group Inc. is a holding company of leading specialty electrical contractors serving the electric utility infrastructure, commercial, and industrial construction markets in the United States and Canada [1] - The company operates through two business segments: Transmission & Distribution (T&D) and Commercial & Industrial (C&I) [1] Business Segments - The T&D segment provides services on electric transmission, distribution networks, substation facilities, clean energy projects, and electric vehicle charging infrastructure [1] - Comprehensive T&D services include design, engineering, procurement, construction, upgrade, maintenance, and repair services [1] - C&I segment offers a broad range of services including design, installation, maintenance, and repair of commercial and industrial wiring for various facilities such as data centers, airports, hospitals, and clean energy projects [1] Recent Events - MYR Group will participate in the KeyBanc Taking Charge: Energy Transition Symposium investor conference on September 18, 2025 [1] - The CEO Rick Swartz and CFO Kelly Huntington will meet with institutional investors during this virtual event [1]
$10,000 in Cash Up for Grabs in F&M Bank's “The Great Briefcase Hunt”
Globenewswire· 2025-08-18 19:52
ARCHBOLD, Ohio, Aug. 18, 2025 (GLOBE NEWSWIRE) -- F&M Bank (“F&M”), an Archbold, Ohio-based bank owned by Farmers & Merchants Bancorp, Inc. (Nasdaq: FMAO), is inviting the community to put on their detective hats for a high-stakes summer challenge, $5,000 for a lucky hunter and $5,000 for a local charity. The Great Briefcase Hunt kicked off Monday, August 18, 2025, and dares residents across the F&M footprint to follow a series of weekly clues leading to a hidden briefcase in a local park. “It’s time to j ...
TOFUTTI ANNOUNCES RESULTS FOR THE THIRTEEN AND TWENTY-SIX WEEKS ENDED JUNE 28, 2025
Globenewswire· 2025-08-18 19:35
Core Viewpoint - Tofutti Brands Inc. reported a decline in net sales and increased competition in the vegan cheese market, leading to a net loss for the recent financial periods [2][4][6]. Financial Performance - For the thirteen weeks ended June 28, 2025, net sales decreased by $254,000, or 11%, to $2,029,000 compared to $2,283,000 for the same period in 2024 [2]. - For the twenty-six weeks ended June 28, 2025, net sales were $3,620,000, a decrease of $875,000, or 19%, from $4,495,000 for the same period in 2024 [4]. - Gross profit for the thirteen weeks ended June 28, 2025, decreased to $618,000 from $667,000 in the prior year, while the gross profit percentage increased slightly to 30% from 29% [3]. - Gross profit for the twenty-six weeks ended June 28, 2025, increased to $1,207,000 from $1,136,000 in the prior year, with a gross profit percentage of 33% compared to 25% [5]. Product Sales - Sales of vegan cheese products decreased to $1,708,000 for the thirteen weeks ended June 28, 2025, down from $1,926,000 in the prior year, attributed to increased competition [2]. - Sales of frozen dessert products also declined to $321,000 for the thirteen weeks ended June 28, 2025, from $357,000 for the same period in 2024 [2]. - For the twenty-six weeks ended June 28, 2025, sales of vegan cheese products decreased to $3,081,000 from $3,735,000, and frozen dessert sales decreased to $539,000 from $700,000 [4]. Losses and Cash Position - The company reported a net loss of $(7,000) or $(0.00) per share for the thirteen weeks ended June 28, 2025, compared to a net loss of $(32,000) or $(0.01) per share for the same period in 2024 [6]. - For the twenty-six weeks ended June 28, 2025, the net loss was $(169,000) or $(0.03) per share, compared to $(335,000) or $(0.06) per share for the same period in 2024 [6]. - As of June 28, 2025, the company had approximately $350,000 in cash and working capital of approximately $2,733,000, down from $462,000 in cash and $2,893,000 in working capital at December 30, 2024 [7]. Company Overview - Tofutti Brands Inc. was founded in 1981 and develops a complete line of plant-based products, including over twenty-five dairy-free foods [8]. - The company serves customers in the United States and twelve other countries, catering to those who are allergic or intolerant to dairy or who wish to maintain a kosher or vegan diet [8].
NVIDIA Blackwell Architecture Comes to GeForce NOW
Globenewswire· 2025-08-18 19:30
GeForce NOW Gamescom 2025 The NVIDIA Blackwell architecture is coming to GeForce NOW, marking the cloud gaming platform’s biggest update yet. News Summary: The NVIDIA Blackwell architecture is coming to GeForce NOW in the platform’s biggest update yet, delivering NVIDIA GeForce RTX 5080-class GPUs to the cloud, including NVIDIA DLSS 4 Multi-Frame Generation for streaming up to 5K resolution at 120 frames per second, new AI-powered features and more.The GeForce NOW game library will double to over 4,500 ...
HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results
Globenewswire· 2025-08-18 18:44
Core Viewpoint - HCW Biologics Inc. reported its financial results for Q2 2025, highlighting significant developments in its clinical trials, business transactions, and financial performance, while also addressing challenges related to funding and compliance with Nasdaq listing requirements [1][8][14]. Business Highlights - The company completed a $5.0 million equity offering on May 15, 2025, to fund clinical trials for HCW9302, aimed at treating autoimmune disorders [2]. - HCW Biologics is actively negotiating licensing agreements for HCW9206, a molecule intended for CAR-T cell production, after suspending its previous licensing agreement with Wugen [6]. - The company is seeking a commercial partner for its T-cell engager compounds, which target cancer antigens and aim to reduce immunosuppression in tumor microenvironments [6]. Financing Transactions - The company extinguished $7.7 million of debt through restructuring or conversion to equity, strengthening its balance sheet [6]. - The equity offering consisted of 671,140 units priced at $7.45 each, with each unit including two warrants for common stock purchase [6]. Clinical Development and Preclinical Results - HCW Biologics plans to initiate a Phase 1 clinical trial for HCW9302 in Q3 2025, targeting alopecia areata, an autoimmune disease with no FDA-approved treatments [6]. - The company has identified second-generation T-cell engagers and immune checkpoint inhibitors for clinical development, with a focus on a pembrolizumab-based fusion molecule showing promise against pancreatic cancer [7]. Financial Results - Revenues for Q2 2025 were $6,550, a significant decrease from $618,854 in Q2 2024, with total revenues for the first half of 2025 at $11,615 compared to $1.7 million in the same period of 2024 [8]. - R&D expenses decreased by 40% in Q2 2025 to $1.2 million, while G&A expenses increased by 31% to $2.1 million [9][10]. - The net loss for Q2 2025 was $1.9 million, down from $15.3 million in Q2 2024, with a six-month net loss of $4.1 million compared to $22.7 million in the prior year [12]. Financial Guidance - As of June 30, 2025, the company expressed substantial doubt regarding its ability to continue as a going concern without additional funding [13]. - HCW Biologics received confirmation from Nasdaq that it met all listing requirements, although it will remain under a "Panel Monitor" for one year [14][15].
PCI Biotech announces discontinuation of development of the PCL technology and evaluation of future operations
Globenewswire· 2025-08-18 18:40
Core Viewpoint - PCI Biotech Holding ASA has decided to discontinue the development of its photochemical lysis (PCL) technology for viral vector manufacturing due to insufficient progress towards its 2025 goals [1][3] Group 1: Development Progress - The company aimed to demonstrate improved yield in mini benchtop bioreactors by 2025, but efforts have not yielded convincing results [1][2] - Additional initiatives were undertaken following the preliminary 2024 Interim Report and the Annual Report 2024, but these did not lead to satisfactory outcomes [2] Group 2: Project Risks and Financial Position - Insufficient progress has extended project timelines and increased resource requirements, raising the overall project risk to an unacceptable level [3] - As of June 2025, PCI Biotech's cash position was NOK 13.6 million, which is expected to sustain operations into Q4 2025, but there is uncertainty regarding the ability to secure additional financing [4] - The company is evaluating its future, considering options such as a potential sale, merger, or complete wind-down of operations [4]
Terra Balcanica Intersects Gold Mineralization Over 72 m and Starts Drill Program At Brezani Target in Bosnia
Globenewswire· 2025-08-18 18:25
Vancouver, British Columbia, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Terra Balcanica Resources Corp. (“Terra” or the “Company”) (CSE:TERA; FRA: UB1) is pleased to announce an expansion of the surface gold skarn system at Brezani and the start of the Phase III drill program at its Viogor-Zanik project, Bosnia and Herzegovina. Highlights The Brezani drillhole BRE23001 located 125 m SSW of the maiden Brezani drillhole intercepted 0.27 g/t Au over 72.3 m including 0.62 g/t Au over 7.5 m. Additionally, two antimony ve ...
Mesa Laboratories Executes Previously-Announced Strategic Financing Plan
Globenewswire· 2025-08-18 18:01
Core Insights - Mesa Laboratories, Inc. has successfully executed its financial strategy by repaying $97.5 million of its 1.375% Convertible Senior Notes due August 2025, utilizing funds drawn from its Credit Agreement [1][2] - The company aims to optimize its capital structure and reduce shareholder dilution while supporting long-term growth [2][5] Financial Performance - The company drew $97.0 million under its Amended and Restated Credit Agreement, increasing the total outstanding balance to $108 million [1] - Interest rate on the Credit Facility is currently 7.18% and is expected to decrease with future Federal Funds Rate reductions, with anticipated interest payments of approximately $2.7 million for Q2 FY 2026 [2][3] Debt Management - Mesa's total net leverage ratio was 3.16 as of June 30, 2025, defined as total debt minus unrestricted cash in excess of $10 million compared to trailing 12 months EBITDA [3] - The company made over $7 million in principal payments in Q1 FY 2026 and expects to make approximately $20 million in principal payments for the remaining quarters of FY 2026 [4] Company Overview - Mesa Laboratories, Inc. is a global leader in designing and manufacturing life science tools and quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries [6]
Notice of the draft decisions on the agenda and general voting ballot for the Annual General Meeting of Shareholders of AUGA Group AB, a company undergoing restructuring, Convened on 29th August 2025
Globenewswire· 2025-08-18 17:26
As previously announced, the Annual General Meeting of Shareholders of AUGA group, AB, a company undergoing restructuring (legal entity code 126264360, registered office at Konstitucijos Ave. 21C, Vilnius, hereinafter – the “Company”) is convened on the initiative and decision of the Company’s Board on 29th August 2025 at 10:00 AM (hereinafter – the “Meeting”). The Company also publishes the general voting ballot. Agenda of the Meeting: Consolidated management report of the Company for the year 2024 and ind ...